IOL Chemicals & Pharmaceuticals Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/nra17tawftu3m41fud3bf533.pdf

Key Takeaways


The Paracetamol Price Shock

Mahajan: "The Paracetamol prices primarily have come near to pre-COVID level, demand is still there, but prices are drastically down from last year's price by 35% to 40%. Although we think that the prices are now stabilized and bottomed out."

Margin Walk

Mahajan: "For already contracted orders the amount is being borne by the company but for upcoming contracts we are negotiating with our customers for passing on these costs to them."

Non-Ibuprofen: The Export Pivot

Singh: "Initially we were targeting about ₹500 crore revenue from non-ibuprofen products this year, but considering the current market situation it looks tough. We will not be able to clock ₹500 crore revenue from non-ibuprofen but surely we will be able to do something around ₹450 crore."

Ibuprofen & Capacity Utilization


Pipeline & Capacity Plans


Guidance & Commitments

CommitmentSpecificsTimeline
Non-ibuprofen revenue~₹450 crore (down from ₹500 crore guided earlier)FY24 full year
Paracetamol price recoveryPrices bottomed; product price likely to improveFrom Q4 FY24
API segment price recoveryPrices bottomed; recovery expectedNext two quarters
Export sales visibilityCommercial orders from customer validationsQ1 or Q2 FY25
Non-ibuprofen revenue growth~25% growthNext two to three years
Ibuprofen capacity utilization85% maintained; scalable to 95% on demand surgeNext two quarters
Overall top-line growth10–12% annualOngoing target
FY25 CAPEX₹150–200 crore, funded from internal accrualsFY25
EBITDA marginsSome improvement expectedQ4 FY24
EBIT margin (API segment)A little higher from current level, aided by regulatory approvals and export mixFY25
Acetic Anhydride contributionPressure expected before meaningful topline contributionCouple more quarters

Key Metrics

MetricQ3 FY24
Total income₹529 cr, flat YoY vs ₹530 cr, down 4.2% QoQ from ₹552 cr
EBITDA₹53 cr, up 6% YoY from ₹50 cr, down 25.4% QoQ from ₹71 cr
EBITDA margin10.0%, up 60 bps YoY from 9.4%, down from 12.9% QoQ
Net profit₹23 cr, down 4.2% YoY from ₹24 cr, down 39.5% QoQ from ₹38 cr
EBIT margin, pharmaceutical segment12.19%
EBIT margin, specialty chemicals segment0.43%
CAPEX₹80 cr, vs ₹75 cr in Q3 FY23 and ₹82 cr in Q2 FY24
Annual CAPEX guidance₹150–200 cr, funded entirely from internal accruals
Non-ibuprofen API revenueSub-₹100 cr for the quarter
Non-ibuprofen share of topline~21%
Ibuprofen capacity utilization85%, lower due to year-end holiday slowdown in overseas markets
Ibuprofen net realization~US$10, stable
Paracetamol price realizationDown 35–40% vs Q4 FY23, now near pre-COVID levels
Non-ibuprofen FY24 revenue target~₹450 cr, revised down from initial ₹500 cr guidance
Ethyl Acetate price changeUp 0.5–1%, stabilized